Trials / Recruiting
RecruitingNCT06735833
MMA Embolization for Refractory Chronic Migraine
Feasibility Study to Evaluate the Initial Safety and Effectiveness of TRUFILL n-BCA Liquid Embolic System in Middle Meningeal Artery Embolization for the Preventive Treatment of Refractory Chronic Migraine
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Middle Meningeal Artery embolization | Bilateral middle meningeal artery embolization using TRUFILL n-BCA liquid embolic system |
Timeline
- Start date
- 2025-04-23
- Primary completion
- 2028-12-25
- Completion
- 2029-05-15
- First posted
- 2024-12-16
- Last updated
- 2026-04-17
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06735833. Inclusion in this directory is not an endorsement.